NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

521.40 -2.30 (-0.44%)

Near 52W Low of ₹498.45

121.5K NSE+BSE Volume

NSE 23 Dec, 2025 12:46 PM (IST)

22,759.1

Market Cap

Below industry Median

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

03 Aug 2017

521.40

-0.44%

Emami (1QFY18): Optimisum continues. Maintain BUY

Buy: Emami Ltd.

HDFC Securities

We expect EPS CAGR of 19% over FY17-20. We value Emami based on P/E of 35x on Jun-19 EPS. Our TP is Rs 1,301. We maintain our BUY rating. Emamis net revenues contracted by a sharp 16% to Rs 5.4bn (vs. expectations of -8%). Domestic business (85% of total) declined by 16%, with an 18% volume decline. International was under pressure, and contracted by 19%. EBITDA/APAT up by -46/-55%. Domestic biz was impacted by channel destocking. Management is confident of a strong growth recovery in 9MFY18 (July recovery was inspiring). We remain optimistic for Emamis domestic business, and expect 14% revenue CAGR over FY17-20.

Emami Ltd. is trading below all available SMAs

Emami Ltd.

23 May 2017

521.40

-0.44%

Emami Ltd Q4FY17 results comment

Results Update: Emami Ltd.

HDFC Securities

Revenue decreased by 20.35% to Rs. 577.58 Cr in Q4FY17 when compared to the previous quarter.

Emami Ltd. has an average target of 656.50 from 6 brokers.

Emami Ltd.

09 May 2017

521.40

-0.44%

Emami (Resuming Coverage): Better days ahead. BUY

Buy: Emami Ltd.

HDFC Securities

Emami is one of the leading and fastest-growing personal and healthcare companies in India. It boasts of an enviable portfolio of household brands such as Boroplus, Navratna, Fair and Handsome, Zandu and Mentho Plus Balm, Kesh King, Sona Chandi and Zandu Chyawanprash and Fast Relief.

Emami Ltd. has an average target of 656.50 from 6 brokers.

Emami Ltd.

08 May 2017

521.40

-0.44%

Emami - 4QFY17 Result Update

Buy: Emami Ltd.

Reliance Securities

Emami has reported below par numbers for the quarter ended March 2017 with consolidated sales of Rs5.8bn (down 4% YoY) and net profit of Rs833mn (up 1.5% YoY). Although domestic revenues grew by 3% YoY, revenues of international business division declined by 38% YoY during the quarter. We expect Emami to report consolidated revenue and earnings CAGR of 14.7% and 18.6% respectively through FY17-19E. Considering Emami's strong brands coupled with market leadership and pricing power, we maintain our BUY recommendation on the stock with Target Price of Rs1,244 (from Rs1,211 earlier). Stagnant Growth in Domestic Business...

Emami Ltd. is trading below all available SMAs

Emami Ltd.

04 Feb 2017

521.40

-0.44%

Emami Ltd Q3FY17 results comment

Results Update: Emami Ltd.

HDFC Securities

Revenue grew by 24.26% to Rs. 725.17 Cr in Q3FY17 when compared to the previous quarter. Also, it rose by 0.19% when compared with Q3FY16.

Emami Ltd.'s price crossed above 30Day SMA today

Emami Ltd.

03 Feb 2017

521.40

-0.44%

EARNING UPDATE - EMAMI

Buy: Emami Ltd.

Chola Wealth Direct

Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales and PAT have grown at a CAGR of 18.4% and 23.2% respectively (FY08-13). Geographical breakup of sales: North (29%), West (27%), South (23%) and East (21%). Export contributes ~10.4% of total revenue. Company...

Promoters unpledged 0.52% of shares in last quarter. Total pledge stands at 9.98% of promoter holdings

Is Emami Ltd. worth buying?

233 Votes:

Buy 74.25%

Sell 17.6%

Hold 8.15%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf